Treatment of Human B Cell Lymphoma with Monoclonal Anti-Idiotype Antibodies

  • E. M. Rankin
  • A. Hekman
Part of the NATO ASI Series book series (NSSA, volume 120)


Human malignant B cell tumours are thought to arise from the proliferation of a single clone of cells (1–4). The immunoglobulin (Ig) that is expressed and in some cases secreted by the tumour cells is limited to the expression of one single VH and VL region, and to a single light chain. The unique variable region of the Ig, the idiotype, may be considered a model tumour marker, since it is found only on the malignant cells. Antibodies directed against this target, anti-idiotype antibodies, would have the potential to destroy malignant tissue while leaving the residual normal lymphoid tissues intact.


Chronic Lymphocytic Leukemia Cell Lymphoma Circulate Tumour Cell Netherlands Cancer Institute Monocyte Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R. Levy, R. Warnke, R. F. Dorfman, and J. Haimovich, The monoclonality of human B cell lymphomas, J. Exp. Med., 145: 1014 (1977).PubMedCrossRefGoogle Scholar
  2. 2.
    P. J. Fialkow, E. Klein, G. Klein, and S. Singh, Immunoglobulin and glucose-6-phosphate dehydrogenase as markers of cellular origin in Burkitt lymphoma, J. Exp. Med., 138: 89 (1973).PubMedCrossRefGoogle Scholar
  3. 3.
    S. E. Salmon, and M. Seligmann, B. cell neoplasia in man, Lancet, 2: 1230 (1974).PubMedCrossRefGoogle Scholar
  4. 4.
    K. R. Schroer, D. E. Briles, J. A. Van Boxel, and J. M. Davie, Idiotypic uniformity of cell surface immunoglobulin in chronic lymphocytic leukaemia. Evidence for monoclonal proliferation, J. Exp. Med., 140: 1416 (1974).PubMedCrossRefGoogle Scholar
  5. 5.
    R. A. Miller, D. G. Maloney, R. Warnke, and R. Levy, Treatment of B cell lymphoma with monoclonal anti-idiotype antibody, N. Engl. J. Med., 306: 517 (1982).PubMedCrossRefGoogle Scholar
  6. 6.
    T. C. Meeker, J. Lowder, D. G. Maloney, R. A. Miller, K. Thielemans, R. Warnke, and R. Levy, A clinical trial of anti-idiotype therapy for B cell malignancy, Blood, 65: 1344 (1985).Google Scholar
  7. 7.
    T. J. Hamblin, A. K. Abdul-ahad, J. Gordon, F. K. Stevenson, and G.T. Stevenson, Preliminary experience in treating lymphocytic leukaemia with antibody to immunoglobulin idiotypes on the cell surfaces, Br. J. Cancer, 42: 495 (1980).PubMedCrossRefGoogle Scholar
  8. 8.
    J. Gordon, A.K. Abdul-Ahad, T. J. Hamblin, F. K. Stevenson, and G.T. Stevenson, Mechanisms of tumour cell escape encountered in treating lymphocytic leukaemia with anti-idiotype antibody, Br. J. Cancer, 49: 547 (1984).PubMedCrossRefGoogle Scholar
  9. 9.
    F. R. Macbeth, F. K. Stevenson, G. T. Stevenson, and J.M.A. Whitehouse, Anti-idiotype antibody therapy of patients with non-Hodgkin’s lymphoma. Proceedings of the Second European Conference on Clinical Oncology and Cancer Nursing, Amsterdam, p. 75 (abstr.) (1983).Google Scholar
  10. 10.
    E. M. Rankin, and A. Hekman, Mouse monoclonal antibodies against the idiotype of human B-cell non-Hodgkin’s lymphomas: Production, characterization and use to monitor the progress of disease, Eur. J. Immunol., 14: 1119 (1984).PubMedCrossRefGoogle Scholar
  11. 11.
    E. M. Rankin, A. Hekman, R. Somers, and W. W. ten Bokkel Huinink, Treatment of two patients with B cell lymphoma with monoclonal anti-idiotype antibodies, Blood, 65: 1373 (1985).PubMedGoogle Scholar
  12. 12.
    L. A. Smets, J. Taminiau, K. Hahlen, F. De Waal, and H. Behrendt, Cell kinetic responses in childhood acute nonlymphocytic leukaemia during high-dose therapy with cytosine arabinoside, Blood, 61: 79 (1983).PubMedGoogle Scholar
  13. 13.
    C. G. Figdor, W. S. Bont, I. Touw, J. de Roos, E. S. Roosnek, and J. E. De Vries, Isolation of functionally different human monocytes by counterflow centrifugation elutriation, Blood, 60: 46 (1982).PubMedGoogle Scholar
  14. 14.
    J. E. De Vries, J. Mendelsohn, and W. S. Bont, The role of target cells, monocytes and Fc-receptor bearing lymphocytes in human spontaneous cell mediated cytotoxicity and antibody-dependent cellular cytotoxicity, J. Immunol., 125: 396 (1980).PubMedGoogle Scholar
  15. 15.
    E. M. Rankin, A. Hekman, C. A. Hoefnagel, and M. R. Hardeman, Dynamic studies of lymphocytes labelled with indium-111 during and after treatment with monoclonal anti-idiotype antibody in advanced B cell lymphoma, Br. Med. J., 289: 1097 (1984).CrossRefGoogle Scholar
  16. 16.
    R. A. Miller, D. G. Maloney, J. McKillop, and R. Levy, In vivo effects of murine hybridoma monoclonal antibody in a patient with T cell leukaemia, Blood, 58:78 (1981).Google Scholar
  17. 17.
    R. A. Miller, and R. Levy, Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody, Lancet, 2: 226 (1981).PubMedCrossRefGoogle Scholar
  18. 18.
    L. M. Nadler, P. Stashenko, R. Hardy, W. D. Kaplan, L. N. Button, D. W. Kufe, K. H,. Antman, and S. F. Schlossman, Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen, Cancer Res., 40: 3147 (1980).PubMedGoogle Scholar
  19. 19.
    A. B. Cosimi, R. C. Burton, R. B. Colvin, G. Goldstein, F. J. Delmonico, M. P. LaQuaglia, N. Tolkoff-Rubin, R. H. Rubin, J. T. Herrin, and P. S. Russell, Treatment of acute renal allograft rejection with OKT3 monoclonal antibody, Transplantation, 32: 535 (1981).PubMedCrossRefGoogle Scholar
  20. 20.
    R. A. Miller, A. R. Oseroff, P. T. Stratte, and R. Levy, Monoclonal antibody therapeutic trials in seven patients with T cell lymphoma, Blood, 62: 988 (1983).PubMedGoogle Scholar
  21. 21.
    R. O. Dillman, D. L. Shawler, R. E. Sobol, H. A. Collins, J. C. Beauregard, S. B. Wormsley, and I. Royston, Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukaemia, Blood, 59: 1036 (1982).PubMedGoogle Scholar
  22. 22.
    E. D. Ball, G. M. Bernier, G. G. Cornwell, O. R. McIntyre, J. F. O’Donnell, and M. W. Fanger, Monoclonal antibodies to myeloid differentiation antigens: In vivo studies of three patients with acute myelogenous leukemia, Blood, 62: 1203 (1983).PubMedGoogle Scholar
  23. 23.
    J. Manaster, J. Fruhling, and P. Stryckmans, Kinetics of lymphocytes in chronic lymphocytic leukemia. 1. Equilibrium between blood and a readily accessible pool, Blood, 41: 425 (1973).PubMedGoogle Scholar
  24. 24.
    H. Theml, F. Trepel, P. Schick, W. Kaboth, and H. Begemann, Kinetics of lymphocytes in chronic lymphocytic leukemia: Studies using continous H-thymidine infusion in two patients, Blood, 42: 623 (1973).Google Scholar
  25. 25.
    J. L. Scott, R. McMiJan, J. V. Marino, and J. G. Davidson, Leukocyte labelling with Chromium. IV. The kinetics of chronic lympho- cytic leukemia lymphocytes, Blood, 41: 155 (1973).PubMedGoogle Scholar
  26. 26.
    T. S. Zimmerman, H. A. Godwin, and S. Perry, Studies of leukocyte kinetics in chronic lymphocytic leukemia, Blood, 31: 277 (1968).Google Scholar
  27. 27.
    A. M. Mauer, S. B. Murphy, A. B. Hayes, and G. V. Dahl, Scheduling and recruitment in malignant cell populations, in: “Growth Kinetics and Biochemical Regulation of Normal and Malignant Cells”, B. Drewinko, R. M. Humphrey, eds., Williams and Wilkins, Baltimore (1977).Google Scholar
  28. 28.
    Z. Steplewski, M. D. Lubeck, and H. Koprowski, Human macrophages armed with murine immunoglobulin IgG2a antibodies to tumours destroy human cancer cells, Science, 221: 865 (1983).PubMedCrossRefGoogle Scholar
  29. 29.
    H. S. Shin, J. S. Economou, G. R. Pasternack, R. J. Johnson, and M. L. Hayden, Antibody mediated suppression of grafted lymphoma: IV. Influence of time of tumour residency in vivo and tumour size upon the effectiveness of suppression by syngeneic antibody, J. Exp. Med., 144: 1274 (1976).PubMedCrossRefGoogle Scholar
  30. 30.
    R. Levy, and R. A. Miller, Tumor therapy with monoclonal antibodies. Fed. Proc., 42: 2650 (1983).PubMedGoogle Scholar
  31. 31.
    J. Sklar, M. L. Cleary, K. Thielemans, J. Gralow, R. Warnke, and R. Levy, Biclonal B cell lymphoma, N. Engl. J. Med., 311: 20 (1984).PubMedCrossRefGoogle Scholar
  32. 32.
    M. Raffeld, L. Neckers, D. L. Longo, and J. Cossman, Spontaneous alteration of idiotype in monoclonal B cell lymphoma, N. Engl. J. Med., 312: 1653 (1985).PubMedCrossRefGoogle Scholar
  33. 33.
    T. Meeker, J. Lowder, M. L. Cleary, S. Stewart, R. Warnke, J. Sklar, and R. Levy, Emergence of idiotype variants during treatment of B cell lymphoma with anti-idiotype antibodies, N. Engl. J. Med., 31: 1658 (1985).CrossRefGoogle Scholar
  34. 34.
    H. Kubagawa, M. Mayumi, W. D. Gathings, J. F. Kearney, and M. D. Cooper, Extent of clonal involvement in B cell malignancies, in: “Leukaemia Research: Advances in Cell Biology and Treatment”, S. B. Murphy and J. R. Gilbert, eds., Elsevier, Amsterdam p. 65 (1983).Google Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • E. M. Rankin
    • 2
  • A. Hekman
    • 1
  1. 1.Antoni von Leeuwenhock HuisNetherlands Cancer InstituteAmerstamUSA
  2. 2.Medical Oncology ClinicGuy’s HospitalLondonUK

Personalised recommendations